C
Corentin Richard
Researcher at Université de Montréal
Publications - 70
Citations - 5035
Corentin Richard is an academic researcher from Université de Montréal. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 13, co-authored 47 publications receiving 2779 citations. Previous affiliations of Corentin Richard include University of Burgundy.
Papers
More filters
Journal ArticleDOI
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
Bertrand Routy,Bertrand Routy,Bertrand Routy,Lisa Derosa,Lisa Derosa,Lisa Derosa,Connie P.M. Duong,Connie P.M. Duong,Maryam Tidjani Alou,Maryam Tidjani Alou,Maryam Tidjani Alou,Romain Daillère,Romain Daillère,Romain Daillère,Aurélie Fluckiger,Aurélie Fluckiger,Meriem Messaoudene,Meriem Messaoudene,Conrad Rauber,Conrad Rauber,Conrad Rauber,Maria Paula Roberti,Maria Paula Roberti,Marine Fidelle,Marine Fidelle,Caroline Flament,Caroline Flament,Vichnou Poirier-Colame,Vichnou Poirier-Colame,Paule Opolon,Christophe Klein,Kristina Iribarren,Laura Mondragón,Nicolas Jacquelot,Nicolas Jacquelot,Nicolas Jacquelot,Bo Qu,Bo Qu,Bo Qu,Gladys Ferrere,Gladys Ferrere,Gladys Ferrere,Céline Clémenson,Céline Clémenson,Laura Mezquita,Jordi Remon Masip,C. Naltet,Solenn Brosseau,Coureche Kaderbhai,Corentin Richard,Hira Rizvi,Florence Levenez,Nathalie Galleron,Benoit Quinquis,Nicolas Pons,Bernhard Ryffel,Veronique Minard-Colin,Patrick Gonin,Jean-Charles Soria,Eric Deutsch,Eric Deutsch,Yohann Loriot,Yohann Loriot,François Ghiringhelli,Gérard Zalcman,François Goldwasser,B. Escudier,B. Escudier,Matthew D. Hellmann,Matthew D. Hellmann,Alexander M.M. Eggermont,Alexander M.M. Eggermont,Didier Raoult,Laurence Albiges,Laurence Albiges,Guido Kroemer,Laurence Zitvogel +76 more
TL;DR: It is found that primary resistance to ICIs can be attributed to abnormal gut microbiome composition, and Antibiotics inhibited the clinical benefit of ICIs in patients with advanced cancer.
Journal ArticleDOI
Cross-reactivity between tumor MHC class I-restricted antigens and an enterococcal bacteriophage.
Aurélie Fluckiger,Aurélie Fluckiger,Romain Daillère,Romain Daillère,Mohamed Sassi,Barbara S. Sixt,Peng Liu,Friedemann Loos,Corentin Richard,Catherine Rabu,Maryam Tidjani Alou,Maryam Tidjani Alou,Maryam Tidjani Alou,Anne Gaëlle Goubet,Anne Gaëlle Goubet,Fabien Lemaitre,Gladys Ferrere,Gladys Ferrere,Lisa Derosa,Lisa Derosa,Lisa Derosa,Connie P.M. Duong,Connie P.M. Duong,Meriem Messaoudene,Andréanne Gagné,Philippe Joubert,Luisa De Sordi,Luisa De Sordi,Laurent Debarbieux,Sylvain Simon,Clara-Maria Scarlata,Maha Ayyoub,Belinda Palermo,Francesco Facciolo,Romain Boidot,Richard J. Wheeler,Ivo G. Boneca,Zsofia Sztupinszki,Krisztián Papp,István Csabai,Edoardo Pasolli,Nicola Segata,Carlos López-Otín,Zoltan Szallasi,Fabrice Andre,Valerio Iebba,Valerio Iebba,Valerio Iebba,Valentin Quiniou,David Klatzmann,Jacques Bou-Khalil,Saber Khelaifia,Didier Raoult,Laurence Albiges,B. Escudier,B. Escudier,Alexander M.M. Eggermont,Fathia Mami-Chouaib,Paola Nisticò,François Ghiringhelli,Bertrand Routy,Nathalie Labarrière,Vincent Cattoir,Guido Kroemer,Laurence Zitvogel +64 more
TL;DR: In renal and lung cancer patients, the presence of the enterococcal prophage in stools and expression of a TMP–cross-reactive antigen by tumors correlated with long-term benefit of PD-1 blockade therapy.
Journal ArticleDOI
Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer
Lisa Derosa,Bertrand Routy,Andrew Maltez Thomas,Valerio Iebba,Gérard Zalcman,Sylvie Friard,Julien Mazieres,Clarisse Audigier-Valette,Denis Moro-Sibilot,François Goldwasser,Carolina Alves Costa Silva,Safae Terrisse,Mélodie Bonvalet,Arnaud Scherpereel,H. Pegliasco,Corentin Richard,François Ghiringhelli,Arielle Elkrief,Antoine Désilets,F. Blanc-Durand,Fabio Cumbo,Aitor Abuin Blanco,Romain Boidot,Sandy Chevrier,Romain Daillère,Guido Kroemer,Laurie Alla,Nicolas Pons,E. Le Chatelier,Nathalie Galleron,Hugo Roume,Agathe Dubuisson,M. Bouchard,Meriem Messaoudene,Damien Drubay,Eric Deutsch,Fabrice Barlesi,David Planchard,Nicola Segata,Stéphanie Martinez,Laurence Zitvogel,Jean-Charles Soria,Benjamin Besse +42 more
TL;DR: In this article , the authors performed shotgun-metagenomics-based microbiome profiling in a large cohort of patients with advanced NSCLC (n = 338) treated with first- or second-line ICIs to prospectively validate the predictive value of fecal Akk.
Journal ArticleDOI
Antibiotics are associated with decreased progression-free survival of advanced melanoma patients treated with immune checkpoint inhibitors.
Arielle Elkrief,Layal El Raichani,Corentin Richard,Meriem Messaoudene,Wiam Belkaid,Julie Malo,Karl Belanger,Wilson H. Miller,Rahima Jamal,Nathalie Letarte,Philip Wong,Bertrand Routy +11 more
TL;DR: Patients who received ATB 30 days prior to the administration of ICI experienced more primary resistance (progressive disease), and progression-free survival was significantly shorter, suggesting that ATB use within 30 days before ICI initiation in patients with advanced melanoma may adversely affect patient outcomes.
Journal ArticleDOI
The Gut Microbiome Associates with Immune Checkpoint Inhibition Outcomes in Patients with Advanced Non-Small Cell Lung Cancer.
Taiki Hakozaki,Corentin Richard,Arielle Elkrief,Arielle Elkrief,Yukio Hosomi,Myriam Benlaifaoui,Iris Mimpen,Safae Terrisse,Safae Terrisse,Safae Terrisse,Lisa Derosa,Lisa Derosa,Lisa Derosa,Laurence Zitvogel,Bertrand Routy,Yusuke Okuma +15 more
TL;DR: The negative influence of antibiotic on the GM composition is demonstrated and the bacteria repertoire in patients experiencing favorable responses to ICI is identified, as well as differences between patients who experienced low- versus high-grade irAE.